Department of Chemical Engineering, Queen's University, Kingston, Ontario, Canada K7L 3N6.
J Control Release. 2010 Apr 2;143(1):53-63. doi: 10.1016/j.jconrel.2009.11.025. Epub 2009 Dec 2.
The ability of trimethylene carbonate (TMC) based elastomers to release bioactive vascular endothelial growth factor (VEGF(165)) and hepatocyte growth factor (HGF) separately and in combined and sequential fashions using an osmotic release mechanism was investigated. A TMC-based elastomer was chosen since TMC degrades without producing potentially harmful acidic degradation products, and its mechanical properties can be tailored by copolymerizing with D,L-lactide (DLLA) and epsilon-caprolactone (epsilon-CL) and by controlling the cross-link density. The bioactivities of released VEGF(165) and HGF were assessed using the proliferation of human aortic endothelial (HAEC) and CCL 208 monkey lung epithelial cell lines. VEGF(165) and HGF were lyophilized separately or together with trehalose, rat serum albumin (RSA) and NaCl. No significant elastomer degradation occurred over the initial 8 weeks, during which the bulk of the embedded growth factors were released. The presence of a low concentration of NaCl in the release media did not affect the viability of HAEC and CCL 208 cells. The TMC-based elastomer was able to provide a sustained release of highly bioactive VEGF(165) and HGF for more than 10 days. When released in combination from the same device, VEGF(165) and HGF were released at similar rates. By preparing a dual-layered cylinder, in which VEGF(165) was in the outer layer and HGF in the inner layer, a constant release of VEGF alone was first obtained, followed by overlapping and constant release of the two growth factors after a period of 4days. This study demonstrates the potential of TMC-based elastomers combined with an osmotic mechanism to release acid-sensitive growth factors in bioactive form alone and in combination, in controlled rates and sequences.
采用渗透释放机制,研究了三亚甲基碳酸酯(TMC)基弹性体分别以及以组合和连续方式释放生物活性血管内皮生长因子(VEGF(165))和肝细胞生长因子(HGF)的能力。选择 TMC 基弹性体是因为 TMC 降解时不会产生潜在有害的酸性降解产物,并且可以通过与 D,L-丙交酯(DLLA)和ε-己内酯(ε-CL)共聚以及控制交联密度来调整其机械性能。使用人主动脉内皮(HAEC)和 CCL 208 猴肺上皮细胞系评估释放的 VEGF(165)和 HGF 的生物活性。VEGF(165)和 HGF 分别或与海藻糖、牛血清白蛋白(RSA)和 NaCl 一起冻干。在最初的 8 周内,弹性体没有发生明显降解,在此期间,大部分嵌入的生长因子被释放。释放介质中存在低浓度的 NaCl 不会影响 HAEC 和 CCL 208 细胞的活力。TMC 基弹性体能够持续释放具有高度生物活性的 VEGF(165)和 HGF 超过 10 天。当从同一装置中组合释放时,VEGF(165)和 HGF 以相似的速率释放。通过制备双层圆柱体,其中 VEGF(165)在外层,HGF 在内层,可以首先获得 VEGF 的恒定释放,然后在 4 天后两个生长因子重叠并恒定释放。本研究表明,TMC 基弹性体与渗透机制相结合,具有以生物活性形式单独和组合、以受控速率和顺序释放酸敏感生长因子的潜力。